- Open Access
MiR-144-3p inhibits gastric cancer progression and stemness via directly targeting GLI2 involved in hedgehog pathway
Journal of Translational Medicine volume 19, Article number: 432 (2021)
Gastric cancer (GC) is the fifth most commonly diagnosed cancer worldwide. Due to the dismal prognosis, identifying novel therapeutic targets in GC is urgently needed. Evidences have shown that miRNAs played critical roles in the regulation of tumor initiation and progression. GLI family zinc finger 2 (GLI2) has been reported to be up-regulated and facilitate cancer progression in multiple malignancies. In this study, we focused on identifying GLI2-targeted miRNAs and clarifying the underlying mechanism in GC.
Paired fresh gastric cancer tissues were collected from gastrectomy patients. GLI2 and miRNAs expression were detected in gastric cancer tissues and cell lines. Bioinformatics analysis was used to predict GLI2-targeted miRNAs and dual-luciferase reporter assay was applied for target verification. CCK-8, clone formation, transwell and flow cytometry were carried out to determine the proliferation, migration, invasion and cell cycle of gastric cancer cells. Tumorsphere formation assay and flow cytometry were performed to detail the stemness of gastric cancer stem cells (GCSCs). Xenograft models in nude mice were established to investigate the role of the miR-144-3p in vivo.
GLI2 was frequently upregulated in GC and indicated a poor survival. Meanwhile, miR-144-3p was downregulated and negatively correlated with GLI2 in GC. GLI2 was a direct target gene of miR-144-3p. MiR-144-3p overexpression inhibited proliferation, migration and invasion of gastric cancer cells. Enhanced miR-144-3p expression inhibited tumorsphere formation and CD44 expression of GCSCs. Restoration of GLI2 expression partly reversed the suppressive effect of miR-144-3p. Xenograft assay showed that miR-144-3p could inhibit the tumorigenesis of GC in vivo.
MiR-144-3p was downregulated and served as an essential tumor suppressor in GC. Mechanistically, miR-144-3p inhibited gastric cancer progression and stemness by, at least in part, regulating GLI2 expression.
Gastric cancer (GC) is the fifth most commonly diagnosed cancer and the fourth leading cause of cancer-related death in the world . Due to dramatic advancement in Helicobacter pylori eradication, nutrition improvement, earlier diagnosis and therapeutic breakthroughs, the incidence of GC has declined in the past few decades. However, the prognosis of GC is still poor and disappointing . Therefore, identifying novel therapeutic targets and clarifying the underlying mechanisms are urgently needed in GC.
MicroRNAs (miRNAs), a class of endogenous small non-coding RNAs, are short in length but powerful in regulation of gene expression . More than 84% miRNAs down-regulate or silence the expression of target genes by directly binding to the 3’-UTR of mRNA . Mountain studies have shown that miRNAs played critical roles in tumor proliferation, apoptosis, invasion, metastasis and drug resistance , etc. For example, miR-203 inhibits proliferation, migration and invasion of gastric cancer cells by downregulating Slug ; miR-1244 inhibits tumor metastasis by targeting FAK in intestinal-type gastric cancer ; miR-200c functions as a tumor suppressor in gastric cancer and overcomes drug resistance during cisplatin chemotherapy .
GLI family zinc finger 2, also known as GLI2, is one of the transcription factors in Hedgehog signaling pathway (HHSP). Previous studies showed that GLI2 was up-regulated and facilitated cancer progression in multiple malignancies, such as glioma , colorectal cancer  and bladder cancer . In this paper, we showed that GLI2 was obviously upregulated in GC and high GLI2 expression indicated a poor survival. In addition, GLI2 is a critical messenger in crosstalk between PI3K/ Akt /mTOR pathway and HHSP. Increased PI3K/AKT/mTOR activity leads to enhanced hedgehog signaling via regulating GLI transcription factors . Therefore, attempting to block or silence the expression of GLI2 will significantly help to suppress gastric cancer progression, and thus GLI2-targeted miRNA might be a good choice for gastric cancer treatment.
In this study, GLI2-targeted miRNA, miR-144-3p, was firstly identified in GC. The subsequent results illuminated that miR-144-3p inhibited gastric cancer progression in vitro and in vivo. What’s more, the study indicated that miR-144-3p attenuated the stemness of GCSCs. Finally, our results revealed that miR-144-3p inhibited gastric cancer progression and stemness via targeting GLI2.
Patients and clinical samples
Twenty-one pairs of fresh gastric adenocarcinoma (confirmed by preoperative biopsy and postoperative pathology) and adjacent normal tissues were collected from patients who undergone gastrectomy in Chinese PLA General Hospital from January 2020 to December 2020. Samples were collected immediately after tumor resection and kept in liquid nitrogen and then transferred to −80 °C refrigerator for preservation. All patients did not receive any adjuvant therapy (such as neoadjuvant chemoradiotherapy) before surgery. Written informed consents were obtained from all patients. This study was approved by the Medical Ethics Committee of Chines PLA General Hospital in accordance with the Declaration of Helsinki.
Cell lines and cell culture
Human gastric cancer cell lines HGC-27, MKN-28, SGC-7901, MGC-803, BGC-823, NCI-N87 and immortalized gastric epithelial cell line GES-1 were purchased from the Cell Bank of Chinese Academy of Sciences (Shanghai, China). Adherent cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM, GIBCO, NY, USA) with 10% fetal bovine serum (FBS) and 1% P/S in a standard condition at 37 °C with 5% CO2. Gastric cancer stem cells (GCSCs) were obtained and cultured as previously described [13, 14]. Briefly, GCSCs were extracted from fresh GC tissues resected in Chinese PLA General Hospital (PLAGH) and cultured in ultra-low-attachment 6-well plates (Corning, NY, USA) with modified DMEM/F12, 2% B27 supplements (Invitrogen, CA, USA), 1% ITS (insulin–transferrin–selenous acid, Corning, NY, USA), 20 ng/ml epidermal growth factor (Peprotech, Hartford, CT, USA), 10 ng/ml basic fibroblast growth factor (Peprotech), 10 ng/ml LIF (Peprotech) and 10 ng/ml gastrin I (Peprotech).
RNA isolation and qRT-PCR
Total RNA from cell lines or tissues was extracted using TRIzol reagent according to the manufacturer’s instructions (Invitrogen). RNA quality and concentrations were determined by Nanodrop 2000 spectrophotometer (ThermoFisher, MA, USA). For mRNA quantification, cDNA was synthesized using a NovoScriptTM All-in-one 1st strand cDNA synthesis SuperMix with gDNA Purge, and qRT-PCR was performed using SYBR™ qPCR SuperMix Plus (Novoprotein, Shanghai, China). For miRNA, the Mir-X miRNA First-Strand Synthesis Kit and qRT-PCR TB Green Kit (Takara, Dalian, China) were used for quantification. All the primers used were listed in Additional file 1: Table S1. The expression levels of mRNA and miRNA were normalized to the expression of GAPDH and U6, respectively. The results were analyzed by the 2−∆∆CT method and each sample was analyzed in triplicate.
Oligonucleotides, plasmids and cell transfection
The miRNA mimics, inhibitors and negative controls were purchased from GenePharma (Shanghai, China). Gain or loss of function of miRNAs were accomplished by transfecting corresponding miRNA mimics or inhibitors, respectively. ΔN-GLI2 cDNA was subcloned into pCMV5 vector with endonucleases. ΔN-GLI2 mRNA, a truncated GLI2 version of GLI2 mRNA (the first 984 bases were deleted), can be translated into ΔN-GLI2 which is more transcriptionally active than full length GLI2 . The GLI2 shRNA plasmid (target sequence: GCAACAAAGCCTTCTCCAA) was synthesized by GeneChem (Shanghai, China). The wild-type GLI2 3ʹ-UTR reporter plasmid containing miRNA binding sites and corresponding mutant-type reporter plasmid were purchased from Promega (#E2920, USA). The mimics, inhibitors and plasmids were transfected into cells by Lipofectamine 2000 reagent (Invitrogen). All the experiments were carried out accordance to the manufacturer’s instructions.
Protein extraction and western blot
Cells were lysed on ice for 20 min using RIPA extraction buffer (Beyotime, Shanghai, China) containing protease inhibitor. Proteins were collected and the concentrations were determined by BCA protein kit (Solarbio, Beijing, China). Then, protein lysates were separated by SDS-PAGE and transferred to PVDF membrane (Millipore, Darmstadt, Germany). The membranes were blocked with 5% defatted milk for 1 h and incubated with primary antibodies overnight at 4 °C. Subsequently, the membranes were incubated with HRP-conjugated secondary antibodies at room temperature for 2 h. The β-Actin expression was used as internal control for normalization. The brands were detected by enhanced ECL chemiluminescence reagent (Beyotime). Details of the antibodies used in experiments were listed in Additional file 1: Table S2.
Cell proliferation assay
The treated and control HGC-27 and SGC-7901 cells were examined by cell counting kit 8 (CCK-8) (Beyotime) to determined cell proliferation. Briefly, cells in logarithmic phase of each group were collected, resuspended, counted and then seeded at a density of 5000 cells per well into 96-well pates. Three wells were assigned for each group. CCK-8 assays were performed at 0, 24, 48, 72 and 96 h after cell culturation. That is, 10 μl CCK-8 reagent (Solarbio) was added to each well and absorbance at 450 nm was measured after the cells were incubated for 1 h at 37 °C. The proliferation curves were plotted to indicate cell viability.
Colone formation assay
Cells of treatment and control groups were harvested and counted respectively. A total of 1000 cells were seeded per well in 6-well plates with complete culture medium. Cells were cultured at 37℃ with 5% CO2 for 10–14 days until visible colonies formed. Cells were fixed with 4% paraformaldehyde for 15 min and then stained with 0.1% crystal violet for 30 min. Colonies were photographed and counted.
Cell cycle and flow cytometry analysis
Cells cultured in 6-well plates were trypsined, collected, centrifuged and the supernatant was removed. Then cells were washed with ice cold PBS and resuspended in 1 mL PBS. For the cell cycle, cells were fixed in 70% ethanol at 4 °C for 12–24 h. Subsequently, the cells were incubated with propidium staining solution with RNase A (Beyotime) at 37 °C for 30 min. The cell cycles were detected on BD flow cytometer (BD Biosciences, NJ, USA). For CD44 expression, cells were suspended in 80 μl binding buffer (Beyotime) and then incubated with 2 μl PE-Cy7 CD44 primary antibody (#560533, BD Biosciences) at 4 °C for 15–20 min in the dark. After centrifugation, the cells were resuspended with 500ul Hank’s Balanced Salt Solution (HBSS) and the expression of CD44 was detected on BD flow cytometer. Data analysis was carried out by FlowJo software (Version 10, Tree Star, USA).
The cell migration and invasion experiments were performed using 8 μm pore size transwell chambers (Corning) in 24-well plates. Cell medium containing 10% FBS was added to 24-well plates 0.6 ml per well. The 200 μl serum-free medium containing certain number of cells were added into each upper chamber. For migration, 4–5 × 104 cells were diluted in 200 μl serum-free medium and added to each chamber. For invasion, the chambers were pre-coated with 50 μl diluted Matrigel (Corning, Matrigel: medium = 1:8), and then 8–10 × 104 cells were diluted in 200 μl serum-free medium and added to each chamber. After incubation at 37 °C for 24 h, cells on the upper surface of chamber were swept by cotton swab slightly. Cells on the bottom of the chamber were fixed with paraformaldehyde for 15 min and stained with crystal violet for 30 min. Cells penetrated were imaged and counted at five random fields.
Dual-luciferase reporter assay
Human embryonic kidney cell HEK293T was used for luciferase reporter assay. Once the cultured cells converged to 40–60%, 100 nM miR-144-3p mimics or negative controls (mimic-NC) were co-transfected with wild type (WT) or mutant type (MUT) GLI2 3’-UTR luciferase reporter plasmids respectively. After transfection for 48 h, a dual luciferase assay system (#E2920, Promega, WI, USA) was applied to determined relative luciferase activities according to the manufacturer’s instruction. The firefly luciferase activity was normalized to Renilla luciferase activity.
The paraffin-embedded tissues were cut into sections of 5 μm in thickness, then the sections were dewaxed and rehydrated. The slides were immersed in EDTA buffer (pH = 8.0) and heated in microwave oven with a specific temperature program for antigen retrieval. After rinsing with PBS, the slides were blocked with 3% BSA solution. Then the slides were incubated with primary antibody at 4 °C over night. Next, slides were incubated with HRP-coupled secondary antibodies at room temperature for 1 h and then 3,3-diaminobenzidine (DAB) was used for visualization of peroxidase reaction. Finally, the slides were re-stained with hematoxylin and photographed under microscope, and the images were analyzed.
In-vivo xenograft assay
Five weeks old male BALB/c nude mice were purchased from Vital River Laboratory Animal Co. (Beijing, China) and raised in Specific Pathogen Free condition. Ten nude mice were randomly divided into negative control (NC) group or miR-144-3p mimic group (5 mice per group). Then, 1 × 106 HGC-27 cells transfected with NC or mimics mixed with Matrigel (Corning) at a 1: 1 ratio. The xenograft model was established by injecting 200 μl abovementioned mixture into the right flanks of the nude mice subcutaneously. Tumor sizes were measured and recorded every 3–4 days with a vernier caliper. Three weeks later, the mice were euthanized. Tumors were dissected and measured. Tumor volume was calculated: V = 1/2×length×width2. All the animal experiments were performed in accordance with the guidelines approved by the Laboratory Animal Ethics Committee of Chinese PLA General Hospital.
GLI2-targeted miRNAs were predicted by online database TargetScan (http://www.targetscan.org/vert_72/), miRDB (http://mirdb.org/), miRanda (http://www.microrna.org/) and Starbase (http://starbase.sysu.edu.cn/index.php), respectively. The Venn diagram (https://bioinfogp.cnb.csic.es/tools/venny/) was used to intersect the predicted results. TCGA (https://www.cancer.gov/about-nci/organization/ccg/research/structural-genomics/tcga) and GEPIA (http://gepia.cancer-pku.cn/) database were used to analyze the GLI2 expression level in gastric cancer and adjacent normal tissues. The online database Kaplan–Meier plotter (http://kmplot.com/analysis/index.php) was applied to analyze survival outcomes. The expression of miRNAs and its correlation with target genes were analyzed based on TCGA database.
SPSS Version 25.0 (IBM Corp, Armonk, NY, USA) was used for statistical analysis in this study. The results are expressed as mean ± standard deviation (SD). Student’s t-test (two-tailed) or analysis of variance (ANOVA) were applied to two or more groups comparison. The correlation between two parameters was examined by Pearson correlation test. GraphPad Prism 8 and ggplot2 package were used for data visualization. *p < 0.05, **p < 0.01, ***p < 0.001, ns = no significance. P < 0.05 was considered statistically significant.
GLI2 is upregulated in gastric cancer and indicates poor survival
According to recent studies, GLI2 is up-regulated in multiple cancers [9,10,11]. In order to determine the expression of GLI2 in gastric cancer, we firstly detected the GLI2 mRNA in 6 gastric cancer cell lines and immortalized gastric epithelial cell line GES-1. Through qRT-PCR, we found that GLI2 was up-regulated in most gastric cancer cell lines compared with GES-1 (Fig. 1a). Then, we further detected the expression of GLI2 protein in GC. In accordance with qRT-PCR, Western blot (WB) results showed that GLI2 protein was highly expressed in most gastric cancer cell lines, especially in HGC-27 and BGC-823 (Fig. 1b). Next, we explored the expression of GLI2 mRNA in gastric cancer tissues through GEPIA and TCGA databases. As is shown in Fig. 1c, d, GLI2 expression was up-regulated in gastric cancer compared with adjacent normal tissues, and the differences were both statistically significant. Subsequently, we detected GLI2 mRNA levels in 21 paired gastric adenocarcinoma and adjacent normal tissues from GC patients and found that GLI2 was highly expressed in 14/21 patients (Fig. 1e). What’s more, WB and IHC showed the protein expression of GLI2 in representative patients (Fig. 1f, g). In addition, based on K-M Plotter database, patients with higher GLI2 expression harvested a lower overall survival (OS) and first progression survival (FPS), indicating that high GLI2 expression predicted poor prognosis in GC (Fig. 1h, i). Collectively, GLI2 was highly expressed in GC and indicated a poor survival.
MiR-144-3p downregulates GLI2 expression in gastric cancer
Considerable studies have shown that miRNAs could modulate gene expression [3, 4, 16]. In order to identify the potential GLI2-targeted miRNAs in GC, online databases including TargetScan, miRDB, miRanda and Starbase were used for bioinformatic prediction. As a result, seven candidate miRNAs (miR-30a-5p, miR-30b-5p, miR-30c-5p, miR-30d-5p, miR-30e-5p, miR-139-5p and miR-144-3p) were obtained when we intersected the predicted results (Fig. 2a). However, among these candidates, we were curious that who was the real player in GC. Therefore, we synthesized the miRNA mimics of these seven candidates and transferred them into four gastric cancer cell lines (HGC-27, BGC-823, SGC-7901, and MGC-803) respectively, and the changes of GLI2 mRNA were detected by qRT-PCR. A heatmap was drawn based on whether the decrease of GLI2 mRNA was greater than 25% (Fig. 2b). The results showed that five miRNA mimics down-regulated GLI2 mRNA expression in at least one gastric cancer cell line, while miR-144-3p down-regulated GLI2 in all the four gastric cancer cell lines (Fig. 2b). Subsequently, the above five kinds of miRNA mimics were transfected into HGC-27 and BGC-823 cell lines, and the changes of GLI2 protein were detected by WB. Consistent with the foregoing results, the GLI2 protein expression decreased most significantly after transfection with miR-144-3p in both GC cell lines (Fig. 2c, d). In short, the above results suggested that miR-144-3p could down-regulate GLI2 expression in GC.
MiR-144-3p is downregulated and negatively correlated with GLI2 expression in gastric cancer
Based on the results mentioned above, we wondered the expression profile of miR-144-3p and its correlation with GLI2 mRNA in GC. Firstly, we quantified the expression level of miR-144-3p in gastric cancer cell lines and GES-1 by qRT-PCR. The results showed that miR-144-3p was down-regulated in most gastric cancer cell lines compared with GES-1 (Fig. 3a). In addition, we detected the relative expression of miR-144-3p in paired gastric cancer and adjacent normal tissues of 21 patients, and the results showed that miR-144-3p was frequently down-regulated in gastric cancer tissues (17/21) (Fig. 3b). What’s more, the correlation between miR-144-3p and GLI2 mRNA expression was analyzed in the gastric cancer tissues of the 21 patients. The results showed a significant negative correlation between miR-144-3p and GLI2 mRNA (Pearson r = − 0.73, p < 0.001) (Fig. 3c). Next, based on the STAD project of TCGA, we analyzed the relative expression of miR-144-3p in gastric cancer and adjacent normal tissues. Similarly, miR-144-3p expression was significantly down-regulated in gastric cancer tissues (p < 0.001) (Fig. 3d). The data of 41 paired cases of gastric cancer and adjacent normal tissues in TCGA also showed that miR-144-3p was low expressed in cancer tissues (p = 0.0075) (Fig. 3e). Moreover, there was a significant negative correlation between miR-144-3p and GLI2 mRNA expression in 372 gastric cancer samples in TCGA (Pearson r = − 0.275, p < 0.001) (Fig. 3f). Generally, these results showed that miR-144-3p expression was downregulated and negatively correlated with GLI2 mRNA in GC.
MiR-144-3p directly targets 3ʹ-UTR of GLI2 mRNA
Based on the previous results of the study, we speculated that GLI2 mRNA was a direct target gene of miR-144-3p. To verify this hypothesis, bioinformatics analysis was applied to predict the miR-144-3p binding sites of GLI2 mRNA 3ʹ-UTR. According to TargetScan, the 1689–1696 sequences of GLI2 mRNA 3ʹ-UTR were the potential binding sites of miR-144-3p (Fig. 4a). Therefore, the wild-type (WT) and mutant-type (MUT) plasmids containing miR-144-3p binding sites were constructed (Fig. 4b), and the dual-luciferase reporter assay was performed in HEK293T. The results showed that the WT-GLI2 luciferase activity was significantly decreased when co-transfected with miR-144-3p mimics (p < 0.01). However, there was no significant change of MUT-GLI2 luciferase activity after co-transfection with miR-144-3p mimics (Fig. 4c). Collectively, the above results indicated that GLI2 was a direct target gene of miR-144-3p.
MiR-144-3p inhibits gastric cancer progression and stemness
Previous studies have shown that miR-144-3p was a critical tumor suppressor in multiple cancers including colorectal cancer , hepatocellular carcinoma , cholangiocarcinoma  etc. However, the function and mechanism of miR-144-3p in GC have not been thoroughly explored. In the following study, we chose to transfect miR-144-3p mimics into HGC-27 and miR-144-3p inhibitor into SGC-7901 to explore the function of miR-144-3p in GC. Firstly, we manipulated expression of miR-144-3p to test its effect on the proliferation ability of gastric cancer cells. After transfection with miR-144-3p mimics, the proliferation ability and the clone formation rate of GC cells were decreased (Fig. 5a–c), while the number of GC cells in G0-G1 phase was increased (Fig. 5d). On the contrary, cell proliferation ability and the rate of clone formation were enhanced after transfection with miR-144-3p inhibitor (Fig. 5e–g), while the number of GC cells in G0-G1 phase was decreased (Fig. 5h). Subsequently, we explored the effect of miR-144-3p abnormal expression on invasion and migration of gastric cancer cells. The results showed that the migration and invasion ability was significantly weakened after transfection with miR-144-3p mimics (Fig. 5i, j) while cell motility was enhanced after transfection with miR-144-3p inhibitor (Fig. 5k, l). In addition, previous evidences suggested that HHSP played an important role in maintenance of cancer cell stemness. Therefore, we speculated that abnormal expressed miR-144-3p could exert an influence on the stemness of GC cells. Then GCSCs were cultured, and miR-144-3p mimics or inhibitor were transfected. As expected, the results showed that after transfected miR-144-3p mimics the tumorsphere formation ability of GCSCs was weakened and CD44 expression was decreased significantly. However, the tumorsphere formation ability was enhanced and CD44 expression was elevated after transfection with miR-144-3p inhibitor (Fig. 5m–p). Finally, we examined the changes of hedgehog target gene (Cyclin D1) , proliferation, invasion, epithelial-mesenchymal transformation (EMT) and stemness related proteins by WB in HGC-27 and SGC-7901 after transfection with miR-144-3p mimics or inhibitor respectively. The results indicated that miR-144-3p inhibited proliferation, invasion, EMT and attenuated the stemness of gastric cancer cells (Fig. 5q). Taken together, these results showed that enhanced miR-144-3p expression inhibited gastric cancer progression and stemness.
GLI2 reverses miR-144-3p-mediated suppression in gastric cancer
The former parts of this study conformed that miR-144-3p down-regulates the GLI2 expression and inhibits the progression of gastric cancer. Nevertheless, it was still unclear that whether miR-144-3p inhibited gastric cancer progression via regulating GLI2. In order to clarify it, rescue experiments were conducted. Firstly, we restored the expression of GLI2 in HGC-27 transfected with miR-144-3p mimics, and the results showed that the tumor suppressive effects of miR-144-3p were reversed (Fig. 6a–f). Subsequently, we knocked down GLI2 expression in SGC-7901 transfected with miR-144-3p inhibitor, and the results showed that knockdown of GLI2 offset the cancer-promoting effect of miR-144-3p inhibitor (Fig. 6g–l). These results showed that miR-144-3p inhibited gastric cancer progression by, at least in part, regulating the expression of GLI2.
MiR‑144-3p inhibits tumorigenesis in vivo
In order to further investigate whether miR-144-3p could inhibit tumor growth in vivo, HGC-27 cells transfected with miR-144-3p NC or miR-144-3p mimics were injected into male BALB/c nude mice subcutaneously (Fig. 7a). Three weeks later, the mice were sacrificed. Tumors were isolated (Fig. 7b), and the volume and weight were measured. The results showed that the tumor volume ([102 ± 72.6] mm3 vs [434 ± 268.8] mm3, p < 0.05) and tumor weight ([0.084 ± 0.034] g vs [0.282 ± 0.15] g, p < 0.05) of miR-144-3p mimics group were significantly lower than those of miR-144-3p NC group (Fig. 7c, d). Obviously, the results showed that miR‑144-3p could serve as a tumor suppressor and inhibit tumorigenesis in vivo. Taken together, our studies indicated that miR‑144-3p inhibited gastric cancer progression and stemness by regulating GLI2 expression (Fig. 7e).
Hedgehog signaling pathway (HHSP), a stemness related and highly conserved pathway, is usually activated during embryonic development and inactive or extremely low expressed in adults . Previous studies have shown that the activation of HHSP was closely related to the initiation and progression of multiple malignant tumors [22,23,24]. GLI2, an end effector of the HHSP, has been reported to be up-regulated and serve as a cancer-promoting gene in several malignant tumors including glioma , colon cancer , bladder cancer , etc. In this study, we showed that GLI2 was frequently up-regulated in GC and high GLI2 expression indicated a poor survival. Although studies have shown that GLI inhibitor GANT61 could inhibit cancer progression in vivo and vitro , there is still a long way from clinical application.
Recently, mountain evidences have shown that miRNAs played pivotal roles in cancer regulation [3, 5]. In fact, more than 84% miRNAs can silence or inhibit the expression of target genes . What’s more, several miRNA-based next generation drugs have exhibited promising therapeutic landscape in cancers [11, 27]. Undoubtedly, therapeutic miRNA or RNAi is an effective method of cancer treatment. Therefore, we wondered that whether there were miRNAs which directly target GLI2 and thus inhibited the progression of gastric cancer. However, no relevant studies have been reported in GC.
In this study, we first identified GLI2-targeted miRNAs through bioinformatic analysis. For the seven candidate miRNAs obtained, we further showed that miR-144-3p could downregulate GLI2 expression most significantly. What's more, we discovered that miR-144-3p was significantly down-regulated in gastric cancer cell lines and tissues. In addition, there was a significantly negative correlation between the expression of miR-144-3p and GLI2 mRNA. Therefore, we speculated that miR-144-3p was a tumor suppressor in GC. Then, the dual-luciferase assay confirmed that miR-144-3p can directly bind to the 3ʹ-UTR of GLI2 mRNA. Briefly, our study revealed for the first time that GLI2 was a direct target gene of miR-144-3p. MiR-144-3p, 20nt in length, is a kind of small non-coding RNA derived from chromosome 17q11.2. Most studies reported that miR-144-3p served as a tumor suppressor in various kinds of cancers such as colorectal cancer , hepatocellular carcinoma , cholangiocarcinoma , oral squamous cell carcinoma , cervical cancer , prostate cancer , glioma  etc. However, miR-144-3p has also been reported to promote the progression of nasopharyngeal carcinoma  and papillary thyroid carcinoma . Meanwhile, the role of miR-144-3p in GC and the underlying mechanism have not been thoroughly explored. In the present study, we revealed that overexpression miR-144-3p inhibited proliferation, migration and invasion of gastric cancer cells. In terms of mechanism, rescue experiments proved that miR-144-3p inhibited gastric cancer progression by, at least in part, regulating GLI2 expression.
Cancer stem cells (CSCs), possessing the ability to initiate tumor growth and sustain self-renewal as well as differentiation, are considered to be responsible for the heterogeneity, drug resistance, metastasis and recurrence of gastric cancer [34,35,36]. Our previous study also showed that the HHSP played a crucial role in stemness maintenance of GCSCs . Therefore, we speculated that abnormally expressed miR-144-3p could exert influence on the stemness of GCSCs by regulating the expression of GLI2. As expected, both tumorsphere formation assay, CD44 expression detected by flow cytometry and stemness related markers (SOX-2, OCT-4, Nanog) detected by WB confirmed that miR-144-3p could attenuate the stemness of gastric cancer cells. In addition, epithelial mesenchymal transformation (EMT) is deeply involved in tumor initiation, invasion and metastasis. Our results also showed that miR-144-3p inhibited EMT in GC, which was in accordance with Liu’s results performed in renal cell carcinoma . Finally, xenograft assay in nude mice further confirmed the tumor suppressor role of miR-144-3p in vivo.
In conclusion, our results indicated that miR-144-3p served as an essential tumor suppressor in gastric cancer. Mechanistically, miR-144-3p inhibited gastric cancer progression and stemness via regulating GLI2 expression. Therefore, manipulation of miR-144-3p expression might provide a promising therapeutic strategy for gastric cancer. However, further studies are expected to detail the role of miR-144-3p/hedgehog/GLI2 axis in GC.
Availability of data and materials
The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.
GLI family zinc finger 2
Gastric cancer stem cells
Hedgehog signalling pathway
Phosphate buffer saline
Fetal bovine serum
Leukemia inhibitory factor
Hank’s balanced salt solution
Quantitative reverse transcription PCR
Short hairpin RNA
The cancer genome atlas
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.
Allemani C, Matsuda T, Di Carlo V, Harewood R, Matz M, Niksic M, et al. Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet. 2018;391(10125):1023–75.
Bhaskaran M, Mohan M. MicroRNAs: history, biogenesis, and their evolving role in animal development and disease. Vet Pathol. 2014;51(4):759–74.
Guo H, Ingolia NT, Weissman JS, Bartel DP. Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature. 2010;466(7308):835–40.
Hayes J, Peruzzi PP, Lawler S. MicroRNAs in cancer: biomarkers, functions and therapy. Trends Mol Med. 2014;20(8):460–9.
Yang L, Liang H, Wang Y, Gao S, Yin K, Liu Z, et al. MiRNA-203 suppresses tumor cell proliferation, migration and invasion by targeting Slug in gastric cancer. Protein Cell. 2016;7(5):383–7.
Wang J, Wen T, Li Z, Che X, Gong L, Yang X, et al. MicroRNA-1224 inhibits tumor metastasis in intestinal-type gastric cancer by directly targeting FAK. Front Oncol. 2019;9:222.
Ghasabi M, Majidi J, Mansoori B, Mohammadi A, Shomali N, Shirafkan N, et al. The effect of combined miR-200c replacement and cisplatin on apoptosis induction and inhibition of gastric cancer cell line migration. J Cell Physiol. 2019;234(12):22581–92.
Huang D, Wang Y, Xu L, Chen L, Cheng M, Shi W, et al. GLI2 promotes cell proliferation and migration through transcriptional activation of ARHGEF16 in human glioma cells. J Exp Clin Cancer Res. 2018;37(1):247.
Tang YA, Chen YF, Bao Y, Mahara S, Yatim S, Oguz G, et al. Hypoxic tumor microenvironment activates GLI2 via HIF-1alpha and TGF-beta2 to promote chemoresistance in colorectal cancer. Proc Natl Acad Sci U S A. 2018;115(26):E5990–9.
Raven PA, Lysakowski S, Tan Z, D’Costa NM, Moskalev I, Frees S, et al. Inhibition of GLI2 with antisense-oligonucleotides: a potential therapy for the treatment of bladder cancer. J Cell Physiol. 2019;234(11):20634–47.
Larsen LJ, Moller LB. Crosstalk of hedgehog and mTORC1 pathways. Cells. 2020;9(10):2316.
Gao Y, Cai A, Xi H, Li J, Xu W, Zhang Y, et al. Ring finger protein 43 associates with gastric cancer progression and attenuates the stemness of gastric cancer stem-like cells via the Wnt-beta/catenin signaling pathway. Stem Cell Res Ther. 2017;8(1):98.
Gao Y, Li J, Xi H, Cui J, Zhang K, Zhang J, et al. Stearoyl-CoA-desaturase-1 regulates gastric cancer stem-like properties and promotes tumour metastasis via Hippo/YAP pathway. Br J Cancer. 2020;122(12):1837–47.
Roessler E, Ermilov AN, Grange DK, Wang A, Grachtchouk M, Dlugosz AA, et al. A previously unidentified amino-terminal domain regulates transcriptional activity of wild-type and disease-associated human GLI2. Hum Mol Genet. 2005;14(15):2181–8.
Ferragut Cardoso AP, Banerjee M, Nail AN, Lykoudi A, States JC. miRNA dysregulation is an emerging modulator of genomic instability. In: Seminars in cancer biology. New York: Academic Press; 2021.
Sun N, Zhang L, Zhang C, Yuan Y. miR-144-3p inhibits cell proliferation of colorectal cancer cells by targeting BCL6 via inhibition of Wnt/beta-catenin signaling. Cell Mol Biol Lett. 2020;25:19.
Li S, Shao J, Lou G, Wu C, Liu Y, Zheng M. MiR-144-3p-mediated dysregulation of EIF4G2 contributes to the development of hepatocellular carcinoma through the ERK pathway. J Exp Clin Cancer Res. 2021;40(1):53.
Chu KJ, Ma YS, Jiang XH, Wu TM, Wu ZJ, Li ZZ, et al. Whole-transcriptome sequencing identifies key differentially expressed mRNAs, miRNAs, lncRNAs, and circRNAs associated with CHOL. Mol Ther Nucleic Acids. 2020;21:592–603.
Katoh Y, Katoh M. Hedgehog signaling pathway and gastric cancer. Cancer Biol Ther. 2005;4(10):1050–4.
Hooper JE, Scott MP. Communicating with hedgehogs. Nat Rev Mol Cell Biol. 2005;6(4):306–17.
Wang D, Hu G, Du Y, Zhang C, Lu Q, Lv N, et al. Aberrant activation of hedgehog signaling promotes cell proliferation via the transcriptional activation of forkhead Box M1 in colorectal cancer cells. J Exp Clin Cancer Res. 2017;36(1):23.
Wu F, Zhang C, Zhao C, Wu H, Teng Z, Jiang T, et al. Prostaglandin E1 inhibits GLI2 amplification-associated activation of the hedgehog pathway and drug refractory tumor growth. Cancer Res. 2020;80(13):2818–32.
Antonucci L, Di Magno L, D’Amico D, Manni S, Serrao SM, Di Pastena F, et al. Mitogen-activated kinase kinase kinase 1 inhibits hedgehog signaling and medulloblastoma growth through GLI1 phosphorylation. Int J Oncol. 2019;54(2):505–14.
Wickstrom M, Dyberg C, Shimokawa T, Milosevic J, Baryawno N, Fuskevag OM, et al. Targeting the hedgehog signal transduction pathway at the level of GLI inhibits neuroblastoma cell growth in vitro and in vivo. Int J Cancer. 2013;132(7):1516–24.
Berman DM, Karhadkar SS, Maitra A, Montes Oca R, Gerstenblith MR, Briggs K, et al. Widespread requirement for Hedgehog ligand stimulation in growth of digestive tract tumours. Nature. 2003;425(6960):846–51.
Chakraborty C, Sharma AR, Sharma G, Doss CGP, Lee SS. Therapeutic miRNA and siRNA: moving from bench to clinic as next generation medicine. Mol Ther Nucleic Acids. 2017;8:132–43.
He L, Liao L, Du L. miR1443p inhibits tumor cell growth and invasion in oral squamous cell carcinoma through the downregulation of the oncogenic gene, EZH2. Int J Mol Med. 2020;46(2):828–38.
Wu J, Zhao Y, Li F, Qiao B. MiR-144-3p: a novel tumor suppressor targeting MAPK6 in cervical cancer. J Physiol Biochem. 2019;75(2):143–52.
Zheng H, Guo Z, Zheng X, Cheng W, Huang X. MicroRNA-144-3p inhibits cell proliferation and induces cell apoptosis in prostate cancer by targeting CEP55. Am J Transl Res. 2018;10(8):2457–68.
Song J, Ma Q, Hu M, Qian D, Wang B, He N. The inhibition of miR-144–3p on cell proliferation and metastasis by targeting TOP2A in HCMV-positive glioblastoma cells. Molecules. 2018;23(12):3259.
Song L, Chen L, Luan Q, Kong Q. miR-144-3p facilitates nasopharyngeal carcinoma via crosstalk with PTEN. J Cell Physiol. 2019;234(10):17912–24.
Liu C, Su C, Chen Y, Li G. MiR-144-3p promotes the tumor growth and metastasis of papillary thyroid carcinoma by targeting paired box gene 8. Cancer Cell Int. 2018;18:54.
Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer. 2005;5(4):275–84.
Takaishi S, Okumura T, Wang TC. Gastric cancer stem cells. J Clin Oncol. 2008;26(17):2876–82.
Visvader JE, Lindeman GJ. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer. 2008;8(10):755–68.
Song Z, Yue W, Wei B, Wang N, Li T, Guan L, et al. Sonic hedgehog pathway is essential for maintenance of cancer stem-like cells in human gastric cancer. PLoS ONE. 2011;6(3):e17687.
Liu F, Chen N, Xiao R, Wang W, Pan Z. miR-144-3p serves as a tumor suppressor for renal cell carcinoma and inhibits its invasion and metastasis by targeting MAP3K8. Biochem Biophys Res Commun. 2016;480(1):87–93.
This work was supported by the National Natural Science Foundation of China (81972790).
Ethics approval and consent to participate
This study was approved by the Medical Ethics Committee of Chines PLA General Hospital in accordance with the Declaration of Helsinki. Written informed consents were obtained from all patients. All the animal experiments were performed in accordance with the guidelines approved by the Laboratory Animal Ethics Committee of Chinese PLA General Hospital and extensive efforts were made to minimize the suffering of animals.
Consent for publication
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Lu, Y., Zhang, B., Wang, B. et al. MiR-144-3p inhibits gastric cancer progression and stemness via directly targeting GLI2 involved in hedgehog pathway. J Transl Med 19, 432 (2021). https://doi.org/10.1186/s12967-021-03093-w
- Gastric cancer
- Cancer stem cells